DexCom’s recent earnings call conveyed a generally positive sentiment, underscored by robust revenue growth and strategic product expansions. The company showcased its advancements in type 2 diabetes ...
DexCom, Inc. DXCM reported third-quarter 2025 adjusted earnings per share (EPS) of 61 cents, which beat the Zacks Consensus ...
The price of shares of digital marketing company Vinco Ventures, Inc. (BBIG) has soared 168.6% so far this year on investors' ...
After dealing with a deployment problem with glucose monitors earlier this year, interim CEO Jake Leach said improving ...
Amid some scrutiny over its latest-generation G7 CGM, Dexcom officials addressed claims on the company's latest earnings call ...
Medical device company DexCom (NASDAQ:DXCM) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales ...
We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as ...
The market awaits DexCom's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter. It's important for new investors to u ...
DexCom, Inc. DXCM is scheduled to report third-quarter 2025 resultson Oct. 30, after the closing bell. In the last reported ...
Dexcom (DXCM) shares slipped in midday trade on Tuesday after short seller Hunterbrook reported three additional deaths linked to the company’s G7 continuous glucose monitor. DXCM’s stock fell nearly ...
The use of CGM has been growing among people without diabetes, including those with prediabetes, particularly with the ...
Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback